Q1 2023 13F Holders as of 3/31/2023
-
Type / Class
-
Equity / Common Stock and Warrants
-
Shares outstanding
-
27.5M
-
Number of holders
-
37
-
Total 13F shares, excl. options
-
9.6M
-
Shares change
-
-173K
-
Total reported value, excl. options
-
$94.8M
-
Value change
-
-$1.67M
-
Number of buys
-
22
-
Number of sells
-
-8
-
Price
-
$9.87
Significant Holders of AN2 Therapeutics, Inc. - Common Stock and Warrants (ANTX) as of Q1 2023
38 filings reported holding ANTX - AN2 Therapeutics, Inc. - Common Stock and Warrants as of Q1 2023.
AN2 Therapeutics, Inc. - Common Stock and Warrants (ANTX) has 37 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 9.6M shares
of 27.5M outstanding shares and own 34.95% of the company stock.
Largest 10 shareholders include RA CAPITAL MANAGEMENT, L.P. (3.77M shares), BVF INC/IL (1.56M shares), CITADEL ADVISORS LLC (1.34M shares), Avidity Partners Management LP (723K shares), VANGUARD GROUP INC (602K shares), BlackRock Inc. (483K shares), Monashee Investment Management LLC (247K shares), GEODE CAPITAL MANAGEMENT, LLC (145K shares), CITIGROUP INC (134K shares), and STATE STREET CORP (96.9K shares).
This table shows the top 37 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.